Tirzepatide
Also known as: Mounjaro (brand), Zepbound (brand), GIP/GLP-1 dual agonist
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved in Australia as a prescription medicine for type 2 diabetes and weight management. Compounded and grey-market versions are not approved.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported ~5 days, supporting once-weekly dosing of the approved injectable product
- Common forms
- Pre-filled injection pen (approved prescription product), Single-dose vials (approved), Compounded/grey-market vials (not approved)
- Research status
- Prescription-only medicine in Australia (approved by the TGA for specified indications). Compounded and grey-market versions are not approved and sit outside the regulated supply chain.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Demonstrated in clinical trials to lower blood glucose in type 2 diabetes
- Shown in trials to support substantial weight reduction with diet and lifestyle
- Reported to reduce appetite and slow gastric emptying
- Reported improvements in some metabolic markers in trial populations
How it is reported to work
Tirzepatide is reported to act on two gut-hormone receptors at once, GIP and GLP-1 - which together influence insulin release, glucagon, appetite and the rate of stomach emptying. This dual mechanism is reported to improve blood-glucose control and reduce appetite. These effects are supported by large, peer-reviewed human clinical trials, distinguishing it from unapproved research peptides.
Background
Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it acts on two gut-hormone pathways rather than one. It is sold under brand names including Mounjaro and Zepbound. Like semaglutide, it is an approved prescription medicine in Australia backed by large human trials, unlike most of the unapproved research peptides catalogued on this site. This page is educational and not medical advice, and it does not recommend use.
What the research actually shows
Tirzepatide has been evaluated in the SURPASS programme (type 2 diabetes) and the SURMOUNT programme (weight management). These randomised trials reported meaningful effects on blood-glucose control and body weight. Results differ between individuals, and the medicine carries side effects that require professional monitoring.
| Programme | Focus | Outcome reported |
|---|---|---|
| SURPASS | Type 2 diabetes | Improved glucose control |
| SURMOUNT | Weight management | Substantial weight reduction |
What it is used for (regulated indications)
In Australia, tirzepatide is prescribed for type 2 diabetes and chronic weight management in eligible patients, as determined by a healthcare professional. The dual GIP/GLP-1 action is sometimes contrasted with single-pathway GLP-1 agonists like semaglutide, though comparisons should be interpreted carefully.
Things to be aware of
As with semaglutide, there is an important difference between the TGA-approved product and compounded or grey-market “tirzepatide” sold outside the regulated supply chain. Unapproved versions cannot be verified for purity or content, which is why independent testing is discussed in this space. Reported side effects include nausea and gastrointestinal effects, with rarer serious reactions possible.
Because tirzepatide is prescription-only, it should only be used under medical supervision. This article explains what tirzepatide is and what the evidence shows; it is not an endorsement and does not direct anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Strong, trial-backed blood-glucose control in type 2 diabetes
- Substantial reported weight reduction alongside diet and lifestyle
- Reported appetite suppression and reduced food cravings
- Once-weekly dosing of the approved product is convenient for many
- Reported improvements in some metabolic markers in trial populations
Common side effects
- Nausea, especially when starting or increasing dose
- Vomiting, diarrhoea or constipation
- Reduced appetite, early fullness and burping
- Fatigue and mild headaches
- Injection-site reactions
Rare / serious side effects
- Pancreatitis (severe, persistent abdominal pain) - seek urgent care
- Gallbladder problems, including gallstones
- Severe dehydration that can affect kidney function
- Allergic or hypersensitivity reactions
- Reports of changes in vision in some diabetic patients
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Tirzepatide. Listed so you can make an informed decision, not to suggest any use is safe.
- Rapid dose escalation that skips the gradual titration is reported to cause severe, prolonged nausea and vomiting
- Severe vomiting and diarrhoea from overuse can cause dehydration, which is reported to lead to acute kidney injury, a known concern with incretin-drug overuse
- Unregulated compounded or grey-market vials are reported to cause dosing errors and overdoses due to inconsistent or unknown concentrations
- Very rapid weight loss from excessive dosing is reported to be associated with muscle-mass loss and gallstone formation
- Combining with other appetite suppressants or GLP-1 products is reported to amplify gastrointestinal and dehydration risks
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite changes are often reported within the first week, while meaningful weight and glucose changes build over several months.
First effects
Appetite drop within days
Noticeable change
Weight/glucose ~4 weeks
Clear results
Steady change by ~12 weeks
Peak effect
Plateau ~6-9 months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Tirzepatide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection (approved pre-filled pen is pre-dosed; compounded vials are reported to be drawn by units) |
|---|---|
| Typical reported dose | Approved regimen is reported to start at 2.5 mg per week and titrate to a maintenance of about 5–15 mg per week |
| Frequency | Once weekly |
| Cycle length | Reported as ongoing weekly treatment under medical supervision rather than a fixed short cycle; stopping is reported to lead to appetite and weight rebound |
Reported reconstitution (mg → units)
Worked example only (the approved pen is already dosed, this applies to compounded vials): a 10 mg vial + 1 mL bacteriostatic water = 10 mg/mL. A 2.5 mg starting dose ≈ 0.25 mL = 25 units on a U-100 insulin syringe; a 5 mg dose ≈ 0.5 mL = 50 units.
Work out the units for your vial → CalculatorThe approved prescription product is reported to be titrated slowly, starting at a low weekly dose and increasing in steps over several weeks to a maintenance dose, specifically to limit nausea. It is reported to be used as ongoing weekly treatment under medical supervision rather than a short cycle, and stopping is commonly reported to lead to appetite and weight rebound. These are reported patterns for the regulated medicine only and are not a recommendation; dosing must be set by a prescriber.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
An alternative incretin medicine that people compare or switch between rather than combine
An amylin analogue studied alongside incretin drugs for added weight effect
Resistance training & protein intake
Commonly paired to limit reported muscle-mass loss during weight loss
Safety notes
As a prescription-only medicine, tirzepatide should only be used under the supervision of a qualified healthcare professional who can assess suitability and monitor side effects such as nausea and gastrointestinal upset, as well as rarer serious reactions. Compounded or grey-market versions are not TGA-approved and their quality cannot be assured. Do not use any version without medical guidance.